Global Blood Therapeutics Inc
NASDAQ:GBT
Intrinsic Value
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorde... [ Read More ]
There is not enough data to reliably calculate the intrinsic value of GBT.
Global Blood Therapeutics Inc's market capitalization is 4.6B USD.
GBT stock price is 68.49 USD.
GBT.
GBT. Open DCF Valuation
GBT. Open Relative Valuation
GBT.
GBT's long-term assets (870m USD) exceed its long-term liabilties (752m USD).
GBT has positive Net Debt. This means that the company has more debt (582m USD) than cash and short-term investments (517m USD).
GBT's Revenue has grown by an exceptional 43% over the past 12 months.
GBT's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -136% to -117%, and is approaching profitability.
GBT's ROE (Return on Equity) has significantly decreased in the last 3 years from -56% to -149%, and is approaching profitability.
GBT has negative Operating Income for the last twelve months.
GBT has negative Net Income for the last twelve months.
GBT's ROE (Return on Equity) for the past 12 months is negative and is equal to -149%.
GBT's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -117%.
GBT has positive Gross Profit for the last twelve months.
GBT has negative Free Cash Flow for the last twelve months.
GBT has negative three-year average ROE (Return on Equity): -68%. The company is not efficient at transforming stockholders' equity into net income.
GBT has negative three-year average ROIC (Return on Invested Capital): -169%. The company is not efficient at using invested capital to generate operating income.
GBT's short-term assets (640m USD) exceed its short-term liabilties (93m USD).
GBT's D/E (Debt to Equity) is very high and is equal to 4.92.
GBT's Altman Z-Score is very low and is equal to -1.45.
GBT doesn't generate enough operating income (-299m USD) to safely cover interest payments on its debt (22m USD).
Fundamental Analysis
Global Blood Therapeutics Inc
Balance Sheet Decomposition
Global Blood Therapeutics Inc
| Current Assets | 640m |
| Cash & Short-Term Investments | 517.2m |
| Receivables | 29.8m |
| Other Current Assets | 93.1m |
| Non-Current Assets | 230.4m |
| Long-Term Investments | 146.9m |
| PP&E | 78.9m |
| Other Non-Current Assets | 4.6m |
| Current Liabilities | 93.1m |
| Accounts Payable | 8.3m |
| Accrued Liabilities | 84.6m |
| Other Current Liabilities | 260k |
| Non-Current Liabilities | 659m |
| Long-Term Debt | 581.9m |
| Other Non-Current Liabilities | 77m |
Earnings Waterfall
Global Blood Therapeutics Inc
|
Revenue
|
234.9m
USD
|
|
Cost of Revenue
|
-4.5m
USD
|
|
Gross Profit
|
230.4m
USD
|
|
Operating Expenses
|
-529.7m
USD
|
|
Operating Income
|
-299.2m
USD
|
|
Other Expenses
|
-23.2m
USD
|
|
Net Income
|
-322.5m
USD
|
Free Cash Flow Analysis
Global Blood Therapeutics Inc
GBT Profitability Score
Profitability Due Diligence
Global Blood Therapeutics Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Global Blood Therapeutics Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
GBT Solvency Score
Solvency Due Diligence
Global Blood Therapeutics Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Score
Global Blood Therapeutics Inc's solvency score is 30/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GBT Price Targets Summary
Global Blood Therapeutics Inc
Ownership
GBT Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
GBT Price
Global Blood Therapeutics Inc
| Average Annual Return | -2.37% |
| Standard Deviation of Annual Returns | 58.41% |
| Max Drawdown | -74% |
| Market Capitalization | 4.6B USD |
| Shares Outstanding | 67 476 200 |
| Percentage of Shares Shorted | 11.05% |
GBT News
Last Important Events
Global Blood Therapeutics Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Global Blood Therapeutics Inc
Company Profile
Global Blood Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. The company is headquartered in South San Francisco, California and currently employs 457 full-time employees. The company went IPO on 2015-08-12. The firm is focused on Oxbryta (voxelotor), which is the Food and Drug Administration (FDA) approved medicine that inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in sickle cell disease (SCD). The company is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase III development to address pain crises associated with the disease, and GBT021601 (GBT601), the Company’s next-generation HbS polymerization inhibitor. The firm is focused on areas of the United States, Europe, the Gulf Cooperation Council (GCC), region of the Middle East, and Latin America.
You don't have any saved screeners yet
